• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Precigen Inc.

    8/13/24 4:05:10 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email
    SC 13D/A 1 ea0211239-13da18kirk_preci.htm AMENDMENT NO. 18 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13D

    (Amendment No. 18)*

    Under the Securities Exchange Act of 1934

     

    PRECIGEN, INC.
    (Name of Issuer)

    Common Stock
    (Title of Class of Securities)

    46122T102

    (CUSIP Number)

     

     

    Third Security, LLC

    1881 Grove Avenue

    Radford, Virginia 24141

    Attention: Marcus E. Smith, Esq.

    (540) 633-7900

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    Copy to:

    John Owen Gwathmey, Esq.

    David I. Meyers, Esq.

    Troutman Pepper Hamilton Sanders LLP

    Troutman Pepper Building

    1001 Haxall Point

    Richmond, Virginia 23219

    (804) 697-1239

     
    August 9, 2024
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box ☐.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 46122T102 Page 2 of 10

     

    1

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    RANDAL J. KIRK

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP

    (a) ☐
    (b) ☒

    3 SEC USE ONLY
    4 SOURCE OF FUNDS

    PF
    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEM 2(d) OR 2(e)
    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

       
    7 SOLE VOTING POWER
       
      116,844,357
       
    8 SHARED VOTING POWER
       
      0
       
    9 SOLE DISPOSITIVE POWER
       
      116,844,357
       
    10

    SHARED DISPOSITIVE POWER

    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    116,844,357
    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    40.5%
    14 TYPE OF REPORTING PERSON
    IN

     

     

     

     

    CUSIP No. 46122T102 Page 3 of 10

     

    1

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    R.J. KIRK DECLARATION OF TRUST

    31-6661283

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP

    (a) ☐
    (b) ☒

    3 SEC USE ONLY
    4 SOURCE OF FUNDS

    PF
    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEM 2(d) OR 2(e)
    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

       
    7 SOLE VOTING POWER
       
      64,547,214
       
    8 SHARED VOTING POWER
       
      0
       
    9 SOLE DISPOSITIVE POWER
       
      64,547,214
       
    10

    SHARED DISPOSITIVE POWER

    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    64,547,214
    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    22.4%
    14 TYPE OF REPORTING PERSON
    OO – trust

     

     

     

     

    CUSIP No. 46122T102 Page 4 of 10

     

    1

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    SUNSET 2020 LLC

    I.R.S. IDENTIFICATION NO.: 84-4795218

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP

    (a) ☐
    (b) ☒

    3 SEC USE ONLY
    4 SOURCE OF FUNDS

    WC
    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEM 2(d) OR 2(e)
    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

       
    7 SOLE VOTING POWER
       
      16,406,828
       
    8 SHARED VOTING POWER
       
      0
       
    9 SOLE DISPOSITIVE POWER
       
      16,406,828
       
    10

    SHARED DISPOSITIVE POWER

    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    16,406,828
    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    5.7%
    14 TYPE OF REPORTING PERSON
    OO – limited liability company

     

     

     

     

    CUSIP No. 46122T102 Page 5 of 10

     

    1

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    THIRD SECURITY, LLC
    I.R.S. IDENTIFICATION NO.: 54-1923091
     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP

    (a) ☐
    (b) ☒

    3 SEC USE ONLY
    4 SOURCE OF FUNDS

    WC
    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEM 2(d) OR 2(e)
    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Virginia

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

       
    7 SOLE VOTING POWER
       
      32,454,536
       
    8 SHARED VOTING POWER
       
      0
       
    9 SOLE DISPOSITIVE POWER
       
      32,454,536
       
    10

    SHARED DISPOSITIVE POWER

    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    32,454,536
    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    11.3%
    14 TYPE OF REPORTING PERSON
    OO – limited liability company

     

     

     

     

    CUSIP No. 46122T102 Page 6 of 10

     

    1

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    KAPITAL JOE, LLC
    I.R.S. IDENTIFICATION NO.: 45-2595931

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP

    (a) ☐
    (b) ☒

    3 SEC USE ONLY
    4 SOURCE OF FUNDS

    WC
    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEM 2(d) OR 2(e)
    ☐
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Virginia

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

       
    7 SOLE VOTING POWER
       
      13,520,789
       
    8 SHARED VOTING POWER
       
      0
       
    9 SOLE DISPOSITIVE POWER
       
      13,520,789
       
    10

    SHARED DISPOSITIVE POWER

    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    13,520,789
    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    4.7%
    14 TYPE OF REPORTING PERSON
    OO – limited liability company

     

     

     

     

    CUSIP No. 46122T102 Page 7 of 10

     

    This Amendment No. 18 (the “Amendment”) amends and supplements the Statement on Schedule 13D, dated March 27, 2014 and filed on April 7, 2014, as amended by Amendment No. 1 dated December 31, 2014 and filed on January 5, 2015, by Amendment No. 2 dated May 31, 2016 and filed June 2, 2016, by Amendment No. 3 dated July 24, 2017 and filed July 26, 2017, by Amendment No. 4 dated October 16, 2017 and filed October 23, 2017, by Amendment No. 5 dated December 29, 2017 and filed on January 2, 2018, by Amendment No. 6 dated January 19, 2018 and filed January 22, 2018, by Amendment No. 7 dated July 3, 2018 and filed July 6, 2018, by Amendment No. 8 dated May 13, 2019 and filed May 15, 2019, by Amendment No. 9 dated May 24, 2019 and filed on May 24, 2019, by Amendment No. 10 dated June 6, 2019 and filed on June 10, 2019, by Amendment No. 11 dated January 1, 2020 and filed on January 6, 2020, by Amendment No. 12 dated January 31, 2020 and filed on February 4, 2020, by Amendment No. 13 dated August 11, 2020 and filed on August 13, 2020, by Amendment No. 14 dated December 17, 2020 and filed on December 21, 2020, by Amendment No. 15 dated October 6, 2022 and filed on October 7, 2022, by Amendment No. 16 dated January 27, 2023 and filed on January 31, 2023, and by Amendment No. 17 dated May 2, 2024 and filed on May 3, 2024 (the “Original Schedule 13D”), relating to the Common Stock, no par value per share (the “Common Stock”), of Precigen, Inc., formerly known as Intrexon Corporation, a Virginia corporation (the “Company”). Mr. Randal J. Kirk (“Mr. Kirk”), the R.J. Kirk Declaration of Trust, a revocable trust established by Mr. Kirk (“RJ DOT”), Third Security, LLC, a Virginia limited liability company that is controlled by Mr. Kirk (“Third Security”), Kapital Joe, LLC, a Virginia limited liability company that is managed by Third Security (“Kapital Joe”), and Sunset 2020 LLC, a Delaware limited liability company that is controlled by Mr. Kirk (“Sunset 2020” and, together with Mr. Kirk, the RJ DOT, Third Security, and Kapital Joe, the “Reporting Persons”) are filing this Amendment to disclose the purchase by RJ DOT of 23,529,411 shares of Common Stock of the Company in an underwritten public offering of 35,294,118 shares of Common Stock of the Company, at a price per share of $0.85, on August 9, 2024 (the “Offering”).

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows:

     

    On August 9, 2024, RJ DOT utilized its working capital to purchase 23,529,411 shares of Common Stock of the Company in the Offering, for an aggregate purchase price of approximately $20,000,000, or $0.85 per share.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows:

     

    The information set forth in Items 3 and 6 is incorporated herein by reference.

     

    RJ DOT acquired the shares disclosed hereunder for investment purposes.

     

     

     

     

    CUSIP No. 46122T102 Page 8 of 10

     

    Other than as disclosed herein, as of the date of this Amendment, none of the Reporting Persons have present plans or proposals which would result in:

     

    (a)The acquisition by any person of additional securities of the Company, or the disposition of securities of the Company;

     

    (b)An extraordinary corporate transaction such as a merger, reorganization or disposition, involving the Company or any of its subsidiaries;

     

    (c)A sale or transfer of a material amount of assets of the Company or any of its subsidiaries;

     

    (d)Any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e)Any material change in the present capitalization or dividend policy of the Company;

     

    (f)Any other material change in the Company’s business or corporate structure, including but not limited to, if the Company is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

     

    (g)Changes in the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person;

     

    (h)Causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i)A class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

     

    (j)Any action similar to any of those actions enumerated above.

     

     

     

     

    CUSIP No. 46122T102 Page 9 of 10

     

    Item 5. Interest in Securities of the Issuer.

     

    Items 5(a) and (b) of the Original Schedule 13D are hereby amended and restated to read in their entirety as follows:

     

    (a) and (b) See items 11 and 13 of the cover pages to this Statement for the aggregate number of shares and percentage of issued and outstanding shares of Common Stock of the Company owned by the Reporting Persons. The percentage ownership is calculated based on 252,419,690 shares of Common Stock issued and outstanding as of April 26, 2024, as disclosed in the Company’s Amended Annual Report on Form 10-K/A for the period ended December 31, 2023 and filed on April 29, 2024 plus (i) 17,605 shares issued to Nancy Agee in connection with her appointment to the Board of Directors of the Company on July 5, 2024, (ii) 35,294,118 shares issued in the Offering and (iii) 739,478 shares representing options that may be exercised by Mr. Kirk within 60 days hereof.

     

    Reporting Person  Amount of Common Stock
    Beneficially
    Owned
       Percent
    of Class
       Sole Power
    to Vote or
    Direct
    the Vote
       Shared
    Power to
    Vote or
    Direct
    the Vote
       Sole Power to
    Dispose or to
    Direct the
    Disposition
       Shared Power to
    Dispose or to
    Direct the
    Disposition
     
    Randal J. Kirk   116,844,357    40.5%   116,844,357    --    116,844,357       -- 
    R.J. Kirk Declaration of Trust   64,547,214    22.4%   64,547,214    --    64,547,214      
    Third Security, LLC   32,454,536    11.3%   32,454,536    --    32,454,536    -- 
    Sunset 2020 LLC   16,406,828    5.7%   16,406,828    --    16,406,828    -- 
    Kapital Joe, LLC   13,520,789    4.7%   13,520,789    --    13,520,789    -- 

     

    Mr. Kirk could be deemed to have indirect beneficial ownership of the shares of Common Stock directly beneficially owned by the RJ DOT, Third Security, Sunset 2020, and Kapital Joe. Mr. Kirk controls RJ DOT, Sunset 2020 and Third Security, which is the manager of Kapital Joe.

     

    (c) Except as disclosed herein, none of the Reporting Persons have engaged in any transactions in the Company’s Common Stock in the past 60 days.

     

    (d) – (e) Not applicable

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Item 6 of the Original Schedule 13D is hereby amended and supplemented to include the responses in Item 4 above.

     

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 1

    Joint Filing Agreement, dated as of August 13, 2024 by and among Randal J. Kirk, the R.J. Kirk Declaration of Trust, Third Security, LLC, Sunset 2020 LLC, and Kapital Joe, LLC.

     

     

     

     

    CUSIP No. 46122T102 Page 10 of 10

     

    SIGNATURES

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 13, 2024

     

      /s/ Randal J. Kirk
      Randal J. Kirk
       
      R.J. KIRK DECLARATION OF TRUST
       
      By: /s/ Randal J. Kirk
        Randal J. Kirk
        Trustee
       
      THIRD SECURITY, LLC
       
      By: /s/ Randal J. Kirk
        Randal J. Kirk
        Manager
       
      SUNSET 2020 LLC
       
      By: /s/ Randal J. Kirk
        Randal J. Kirk
        Manager
       
      KAPITAL JOE, LLC
       
      By: /s/ Randal J. Kirk
        Randal J. Kirk
        Manager

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit 1 Joint Filing Agreement, dated as of August 13, 2024, by and among Randal J. Kirk, the R.J. Kirk Declaration of Trust, Third Security, LLC, Sunset 2020 LLC, and Kapital Joe, LLC.

     

     

     

    Get the next $PGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precigen Reports First Quarter 2025 Financial Results and Business Updates

      PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

      5/14/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Reports Full Year 2024 Financial Results and Business Updates

      FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory MedicinePRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoffCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launchCompany ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending i

      3/19/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Precigen Inc.

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      8/13/24 4:05:10 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      5/3/24 8:01:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

      SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

      2/27/24 1:48:40 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Financials

    Live finance-specific insights

    See more
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

      GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

      12/27/24 9:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

      GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357

      8/9/24 8:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Tennant Phil

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:06:44 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Shah Rutul R

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:52 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Lehr Donald P.

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:35 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, IP Affairs Perez Jeffrey Thomas bought $50,000 worth of shares (58,823 units at $0.85), increasing direct ownership by 9% to 743,097 units (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 5:09:47 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kirk Randal J bought $19,999,999 worth of shares (23,529,411 units at $0.85) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 4:15:11 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kirk Randal J bought $136,327 worth of shares (96,686 units at $1.41) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      12/29/23 7:30:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Precigen Inc.

      10-Q - PRECIGEN, INC. (0001356090) (Filer)

      5/14/25 4:23:03 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PRECIGEN, INC. (0001356090) (Filer)

      5/14/25 4:19:18 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Precigen Inc.

      PRE 14A - PRECIGEN, INC. (0001356090) (Filer)

      5/6/25 4:15:29 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Precigen downgraded by JP Morgan

      JP Morgan downgraded Precigen from Neutral to Underweight

      3/22/24 7:52:12 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Precigen

      JP Morgan initiated coverage of Precigen with a rating of Neutral

      5/23/23 7:32:58 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Precigen with a new price target

      Cantor Fitzgerald initiated coverage of Precigen with a rating of Overweight and set a new price target of $7.00

      11/18/22 7:56:19 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Precigen Reports First Quarter 2025 Financial Results and Business Updates

      PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

      5/14/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

      –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

      7/23/24 8:01:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care